Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM726HX)

Drug Name
MGCD-0103 Drug Info
Synonyms
Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide
Therapeutic ClassAnticancer Agents
Cross-matching ID
PubChem CID
9865515
ChEBI ID
CHEMBL94525
CAS Number
CAS 726169-73-9
TTD Drug ID
D00FHR
VARIDT Drug ID
DR00735

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
ECM-receptor interaction 2.29 0.00e+0 80/88 (90.91%) TNC;COL1A1;LAMB1;...
Mucin type O-glycan biosynthesis 2.01 0.00e+0 20/36 (55.56%) GALNT12;GALNT7;B4GALT5;...
Proteoglycans in cancer 1.99 3.73e-3 172/205 (83.9%) PRKCA;CDKN1A;COL1A1;...
Complement and coagulation cascades 1.96 5.60e-3 76/85 (89.41%) PLAT;CD55;C3;...
Hematopoietic cell lineage 1.95 6.72e-3 90/99 (90.91%) CD55;ITGA6;IL6;...
African trypanosomiasis 1.94 5.60e-3 32/37 (86.49%) F2RL1;PRKCA;IL6;...
Rap1 signaling pathway 1.93 6.40e-3 184/210 (87.62%) PRKCA;PDGFRA;RAP1GAP;...
Malaria 1.89 9.80e-3 44/50 (88%) CXCL8;IL6;IL1B;...
Dilated cardiomyopathy 1.89 8.71e-3 86/96 (89.58%) ITGA6;DES;TNNC1;...
Melanogenesis 1.89 7.84e-3 74/101 (73.27%) PRKCA;FZD6;TCF7L2;...
Amoebiasis 1.88 8.14e-3 99/102 (97.06%) CXCL8;PRKCA;CXCL1;...
Hypertrophic cardiomyopathy 1.88 7.46e-3 81/90 (90%) ITGA6;IL6;DES;...
Focal adhesion 1.88 6.89e-3 180/201 (89.55%) PRKCA;TNC;COL1A1;...
Hippo signaling pathway 1.87 6.40e-3 120/186 (64.52%) FZD6;AREG;SERPINE1;...
Transcriptional misregulation in cancer 1.87 5.97e-3 158/192 (82.29%) CXCL8;CDKN1A;PLAT;...
Protein digestion and absorption 1.86 8.40e-3 78/103 (75.73%) COL1A1;SLC1A1;ATP1B1;...
Arrhythmogenic right ventricular cardiomyopathy 1.86 8.56e-3 70/77 (90.91%) ITGA6;TCF7L2;DES;...
Axon guidance 1.84 1.06e-2 151/182 (82.97%) PRKCA;ABLIM1;FYN;...
Salivary secretion 1.82 1.24e-2 76/93 (81.72%) PRKCA;ADRB2;ATP1B1;...
Apelin signaling pathway 1.79 1.40e-2 117/137 (85.4%) PLAT;GNG11;JAG1;...
Circadian entrainment 1.79 1.44e-2 85/97 (87.63%) PRKCA;GNG11;GNG4;...
Folate biosynthesis 1.78 1.48e-2 23/26 (88.46%) AKR1C3;AKR1B1;MOCOS;...
Thyroid hormone synthesis 1.78 1.46e-2 66/75 (88%) PRKCA;ATP1B1;PRKACB;...
Glutamatergic synapse 1.77 1.54e-2 97/114 (85.09%) PRKCA;SLC1A1;GNG11;...
Pathways in cancer 1.76 1.68e-2 474/531 (89.27%) CXCL8;PRKCA;CDKN1A;...
Inflammatory mediator regulation of TRP channels 1.76 1.62e-2 82/98 (83.67%) F2RL1;PRKCA;IGF1;...
Legionellosis 1.75 1.60e-2 51/57 (89.47%) CXCL8;CXCL1;C3;...
Long-term potentiation 1.75 1.66e-2 61/67 (91.04%) PRKCA;RPS6KA1;RPS6KA2;...
Adrenergic signaling in cardiomyocytes 1.71 1.70e-2 130/150 (86.67%) PRKCA;ADRB2;ATP1B1;...
Wnt signaling pathway 1.71 1.68e-2 124/166 (74.7%) PRKCA;FZD6;TLE1;...
Glycosylphosphatidylinositol (GPI)-anchor biosynthesis -1.56 3.61e-2 20/26 (76.92%) DPM2;PIGQ;PIGP;...
Pathways of neurodegeneration -1.57 3.82e-2 354/475 (74.53%) UBA1;PSMA2;SDHB;...
DNA replication -1.57 4.06e-2 34/36 (94.44%) PCNA;PRIM2;POLD3;...
Fanconi anemia pathway -1.58 4.10e-2 36/54 (66.67%) FANCA;BRIP1;BRCA2;...
Nucleotide excision repair -1.65 2.51e-2 40/47 (85.11%) ERCC1;ERCC5;CUL4A;...
RNA transport -1.69 1.51e-2 128/186 (68.82%) RPP40;EIF1AX;GEMIN4;...
Ubiquitin mediated proteolysis -1.78 7.33e-3 87/140 (62.14%) CUL2;ELOB;PIAS3;...
Homologous recombination -1.79 7.38e-3 35/41 (85.37%) BRIP1;POLD3;BRCC3;...
RNA polymerase -1.82 4.74e-3 23/31 (74.19%) POLR2I;POLR3K;POLR1C;...
Huntington disease -1.85 2.25e-3 233/306 (76.14%) NDUFB6;EP300;ATP5MC2;...
Parkinson disease -1.97 8.46e-4 176/249 (70.68%) UBA1;PSMA2;SDHB;...
Ribosome biogenesis in eukaryotes -1.98 0.00e+0 52/108 (48.15%) CSNK2A2;DROSHA;NXF2;...
Amyotrophic lateral sclerosis -2.00 0.00e+0 267/364 (73.35%) NOS2;NDUFB6;ATP5MC2;...
Collecting duct acid secretion -2.04 0.00e+0 22/27 (81.48%) ATP4A;ATP6V1B1;TCIRG1;...
Spliceosome -2.18 0.00e+0 101/150 (67.33%) THOC1;LSM8;DDX5;...
Proteasome -2.28 0.00e+0 44/46 (95.65%) PSMD14;POMP;PSMA6;...
Oxidative phosphorylation -2.45 0.00e+0 93/133 (69.92%) SDHB;NDUFA9;NDUFB6;...
Ribosome -2.73 0.00e+0 113/158 (71.52%) RPL34;RPL19;RPL3;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Bone marrow
Neuroblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SH-SY5Y CVCL_0019 Homo sapiens 0.04uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.04uM - 10uM 24H
Normal (Epithelial)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HME1 CVCL_2950 Homo sapiens 0.04uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.04uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.04uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 0.04uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
1HAEo- CVCL_0128 Homo sapiens 10uM 24H
HEK293 CVCL_0045 Homo sapiens 0.04uM - 10uM 24H
NL20 CVCL_0461 Homo sapiens 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 10uM 6H, 24H
A549/Asc-1 CVCL_YA87 Homo sapiens 0.04uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
Normal (Fibroblast)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HFL1 CVCL_4295 Homo sapiens 10uM 24H
IMR-90 CVCL_0347 Homo sapiens 10uM 24H
WI-38 CVCL_0579 Homo sapiens 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.04uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.04uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 6H, 24H
SK-L CVCL_1699 Homo sapiens 0.04uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.04uM - 10uM 24H